|Dr. Gerrit Klaerner||Founder, Pres, CEO & Exec. Director||719.98k||N/A||1972|
|Mr. Geoffrey M. Parker||COO, CFO & Exec. VP||502.33k||N/A||1965|
|Dr. Wilhelm Stahl||Exec. VP & CTO||472.06k||18.61k||1960|
|Mr. Robert L. McKague J.D.||Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer||486.46k||N/A||N/A|
|Dr. Dawn Parsell Ph.D.||Exec. VP of Clinical Devel.||504.92k||666.12k||1963|
|Ms. Annie Yoshiyama||VP of Fin. & Chief Accounting Officer||N/A||N/A||1983|
|Jackie Cossmon||VP of Investor Relations & Communications||N/A||N/A||N/A|
|Mr. Edward J. Hejlek Esq., J.D.||Exec. VP of Intellectual Property||N/A||N/A||1956|
|Mr. Marc Cobo||Consultant||N/A||N/A||1980|
Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Tricida, Inc.’s ISS Governance QualityScore as of December 3, 2020 is 7. The pillar scores are Audit: 4; Board: 4; Shareholder Rights: 8; Compensation: 9.